- Sativex for the management of multiple sclerosis symptoms (PubMed)
- THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (PubMed)
- Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (PubMed)
- Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors(PubMed)
- Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial (PubMed)
- Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis(PubMed)
- Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis(PubMed)
- A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis (PubMed)
- Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain(PubMed)
- Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain (PubMed)